We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

95 hedge funds and large institutions have $853M invested in Avidity Biosciences in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 29 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $739M → $853M (+$114M)

1.64% more ownership

Funds ownership: 90.15% → 91.8% (+1.6%)

5% less funds holding

Funds holding: 100 → 95 (-5)

14% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 29

29% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 17

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
95
Holders Change
-5
Holders Change %
-5%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
12
Increased
25
Reduced
29
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$18.1M
2
MWNA
Marshall Wace North America
New York
+$7.83M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$3.97M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$3.63M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.52M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$5.49M
2
ACM
Alethea Capital Management
Washington
-$5.1M
3
AWA
Aaron Wealth Advisors
Illinois
-$4.2M
4
Goldman Sachs
Goldman Sachs
New York
-$3.98M
5
SCM
Soleus Capital Management
Connecticut
-$2.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
NL
51
NWAM LLC
Washington
$560K -$216K -9,267 -29%
TD Asset Management
52
TD Asset Management
Ontario, Canada
$540K – – –
JP Morgan Chase
53
JP Morgan Chase
New York
$427K +$49.8K +2,139 +14%
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$420K -$558 -24 -0.1%
Susquehanna International Group
55
Susquehanna International Group
Pennsylvania
$415K -$402K -17,286 -51%
PIM
56
Platinum Investment Management
Australia
$371K – – –
Marshall Wace
57
Marshall Wace
United Kingdom
$367K +$345K +14,833 New
ProShare Advisors
58
ProShare Advisors
Maryland
$361K +$30.3K +1,301 +10%
GGHC
59
Gilder Gagnon Howe & Co
New York
$360K +$32.9K +1,414 +11%
DY
60
Dowling & Yahnke
California
$340K – – –
DekaBank Deutsche Girozentrale
61
DekaBank Deutsche Girozentrale
Germany
$320K – – –
VOYA Investment Management
62
VOYA Investment Management
Georgia
$315K – – –
MIM
63
MetLife Investment Management
New Jersey
$303K – – –
Invesco
64
Invesco
Georgia
$279K +$263K +11,296 New
AllianceBernstein
65
AllianceBernstein
Tennessee
$264K +$249K +10,700 New
TYCC
66
Texas Yale Capital Corp
Florida
$247K – – –
E
67
Ergoteles
New York
$232K +$219K +9,400 New
MLICM
68
Metropolitan Life Insurance Company (MetLife)
New York
$232K +$9.79K +421 +5%
PPA
69
Parametric Portfolio Associates
Washington
$220K +$207K +8,903 New
VEA
70
Virtus ETF Advisers
New York
$213K -$12.2K -525 -6%
Russell Investments Group
71
Russell Investments Group
United Kingdom
$203K – – –
Millennium Management
72
Millennium Management
New York
$200K -$1.98M -84,996 -91%
Royal Bank of Canada
73
Royal Bank of Canada
Ontario, Canada
$169K -$6.44K -277 -4%
TRCT
74
Tower Research Capital (TRC)
New York
$160K +$118K +5,056 +357%
UBS Group
75
UBS Group
Switzerland
$94K -$629K -27,056 -88%
1 2
3
4 5

RNAM Hedge Fund Activity: Q2 2021 in Review

95 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2021, worth a combined $853M — up 15% from $739M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of RNAM and 12 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 25 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $18.1M. The largest seller was Cormorant Asset Management, cutting an estimated $5.49M.

  • 95 institutional investors held Avidity Biosciences (RNAM) as of Q2 2021, down from 100 in Q1 2021.
  • Funds reported $853M of Avidity Biosciences stock for Q2 2021, up 15% quarter-over-quarter.
  • 12 funds opened new Avidity Biosciences positions in Q2 2021 and 17 closed out, a net change of -5 holders.
  • The largest Avidity Biosciences buyer in Q2 2021 was T. Rowe Price Associates, an estimated $18.1M added.
  • The largest Avidity Biosciences seller in Q2 2021 was Cormorant Asset Management, an estimated $5.49M sold.

Based on aggregated 13F filings for Q2 2021.